Price T Rowe Associates Inc Xeris Biopharma Holdings, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 130,968 shares of XERS stock, worth $390,284. This represents 0.0% of its overall portfolio holdings.
Number of Shares
130,968
Previous 125,635
4.24%
Holding current value
$390,284
Previous $278,000
6.12%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding XERS
# of Institutions
133Shares Held
57MCall Options Held
126KPut Options Held
45K-
Black Rock Inc. New York, NY10.3MShares$30.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.66MShares$22.8 Million0.0% of portfolio
-
Caxton Corp Princeton, NJ5.11MShares$15.2 Million61.49% of portfolio
-
Bio Impact Capital LLC Cambridge, MA4.83MShares$14.4 Million1.75% of portfolio
-
State Street Corp Boston, MA3.26MShares$9.71 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $405M
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...